Inhibrx Biosciences, Inc. (INBX)
88.70
-1.83
(-2.02%)
USD |
NASDAQ |
Oct 13, 12:37
Inhibrx Biosciences Net Income (Quarterly) : -36.65M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -36.65M |
| March 31, 2026 | -33.44M |
| December 31, 2025 | -32.83M |
| September 30, 2025 | -35.26M |
| June 30, 2025 | -28.65M |
| March 31, 2025 | -43.31M |
| December 31, 2024 | -47.86M |
| Date | Value |
|---|---|
| September 30, 2024 | -43.86M |
| June 30, 2024 | 1.858B |
| March 31, 2024 | -78.71M |
| December 31, 2023 | -93.60M |
| September 30, 2023 | -51.79M |
| June 30, 2023 | -47.05M |
| March 31, 2023 | -48.92M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
| Anika Therapeutics, Inc. | 3.309M |
| BioCryst Pharmaceuticals, Inc. | 78.40M |
| Imunon, Inc. | -2.814M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 36.65M |
| EPS Diluted (Quarterly) | -2.339 |
| Enterprise Value | 1.380B |
| Earnings Yield | -10.01% |
| Normalized Earnings Yield | -10.01 |